
    
      TAK-875 is being developed at Takeda Development Center, Inc. as an adjunct to diet and
      exercise to improve glycemic control in patients with T2DM.

      This study will investigate TAK-875 in participants with type 2 diabetes mellitus who have
      been treated with only diet and exercise for at least 12 weeks prior to Screening, who have
      taken â‰¤7 days of any antidiabetic agent within the 12 weeks prior to Screening, and whose
      glycemic control is inadequate.
    
  